Tobias Deuse
Overview
Explore the profile of Tobias Deuse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
1727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, White K, Olroyd A, Wang C, Caruso C, Gattis C, et al.
iScience
. 2025 Jan;
28(1):111492.
PMID: 39758817
Hypoimmune (HIP) allogeneic cell therapeutics hold the promise to allow off-the-shelf treatments for a broad patient population. Our HIP approach includes the depletion of major histocompatibility complex (MHC) class I...
2.
YaQoub L, Caughron H, Qasim A, Tolstrop K, Delling F, Watt C, et al.
JACC Adv
. 2024 Jun;
3(4):100862.
PMID: 38939678
No abstract available.
3.
Hu X, White K, Young C, Olroyd A, Kievit P, Connolly A, et al.
Cell Stem Cell
. 2024 Feb;
31(3):334-340.e5.
PMID: 38335966
Allogeneic transplantation of pancreatic islets for patients with difficult-to-control diabetes mellitus is severely hampered by the requirement for continuous immunosuppression and its associated morbidity. We report that allogeneic transplantation of...
4.
Elde S, Baccouche B, Mullis D, Leipzig M, Deuse T, Krishnan A, et al.
J Thorac Cardiovasc Surg
. 2024 Feb;
168(2):581-592.e4.
PMID: 38320627
Objective: The objective of this study is to evaluate survival for combined heart-lung transplant (HLTx) recipients across 4 decades at a single institution. We aim to summarize our contemporary practice...
5.
Loebe M, Deuse T, Sinha N, Koster A, Erdoes G
J Cardiothorac Vasc Anesth
. 2024 Jan;
38(3):635-637.
PMID: 38195272
No abstract available.
6.
Gravina A, Tediashvili G, Zheng Y, Iwabuchi K, Peyrot S, Roodsari S, et al.
Cell Stem Cell
. 2023 Nov;
30(11):1538-1548.e4.
PMID: 37922880
Immune rejection of allogeneic cell therapeutics remains a major problem for immuno-oncology and regenerative medicine. Allogeneic cell products so far have inferior persistence and efficacy when compared with autologous alternatives....
7.
Hu X, White K, Olroyd A, DeJesus R, Dominguez A, Dowdle W, et al.
Nat Biotechnol
. 2023 May;
42(3):413-423.
PMID: 37156915
Genetic engineering of allogeneic cell therapeutics that fully prevents rejection by a recipient's immune system would abolish the requirement for immunosuppressive drugs or encapsulation and support large-scale manufacturing of off-the-shelf...
8.
Hu X, Gattis C, Olroyd A, Friera A, White K, Young C, et al.
Sci Transl Med
. 2023 Apr;
15(691):eadg5794.
PMID: 37043559
Transplantation of allogeneic pancreatic donor islets has successfully been performed in selected patients with difficult-to-control insulin-dependent diabetes and impaired awareness of hypoglycemia (IAH). However, the required systemic immunosuppression associated with...
9.
Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, et al.
Nat Commun
. 2023 Apr;
14(1):2020.
PMID: 37037829
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex, and many patients experience treatment delays or cannot be treated at all. Although current allogeneic CAR products have the...
10.
Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, et al.
Nat Biotechnol
. 2023 Jan;
41(5):717-727.
PMID: 36593395
Allogeneic cell therapeutics for cancer therapy or regenerative medicine are susceptible to antibody-mediated killing, which diminishes their efficacy. Here we report a strategy to protect cells from antibody-mediated killing that...